Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979629P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979629P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979628P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979628P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962DP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962DP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979627P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979627P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979622P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979622P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962GP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962GP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797961YP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797961YP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962JP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962JP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962IP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962IP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962HP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962HP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962EP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962EP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962CP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962CP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979625P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979625P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962BP1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-135797962BP1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets
Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979623P1 (U.S. Pat. App. May. 2, 2017)
Cite Document
APIXABAN FORMULATIONS, 13/579,796, No. 1-1-US-1357979623P1 (U.S. Pat. App. May. 2, 2017)
+ More Snippets